- A novel prediction score for predicting the baseline risk of recurrence of stage I–II endometrial carcinoma
-
Takahashi , Yunokawa M, Sasada S, Takehara Y, Miyasaka N, Kato T, Tamura K
- KMID: 2429577
- J Gynecol Oncol.
- 2019 Jan;30(1):e8.
- doi: 10.3802/jgo.2019.30.e8
OBJECTIVE: To develop and validate a 3-year recurrence prediction score (RPS) system for predicting the baseline risk of recurrence of stage I–II endometrial carcinoma. METHODS: We reviewed 427 patients with International... -
- CITED
-
- Close
- SHARE
-
- Close
- Baseline risk of recurrence in stage I–II endometrial carcinoma
-
Sasada S, Yunokawa M, Takehara Y, Ishikawa M, Ikeda S, Kato T, Tamura K
- KMID: 2395236
- J Gynecol Oncol.
- 2018 Jan;29(1):e9.
- doi: 10.3802/jgo.2018.29.e9
OBJECTIVE: Though there are no evidences that postoperative therapy improves overall survival (OS) in stage I–II endometrial carcinoma, many women receive postoperative radiation or chemotherapy. This study aimed to investigate... -
- CITED
-
- Close
- SHARE
-
- Close
- Clinical utility of CA-125 in the management of uterine carcinosarcoma
-
Matsuo K, Ross MS, Yunokawa M, Johnson MS, Machida H, Omatsu K, Klobocista MM, Im DD, Satoh S, Baba T, Ikeda Y, Bush SH, Hasegawa K, Blake EA, Takekuma M, Shida M, Nishimura , Adachi S, Pejovic T, Takeuchi S, Yokoyama T, Ueda Y, Iwasaki K, Miyake TM, Yanai S, Nagano T, Takano T, Shahzad MM, Ueland FR, Kelley JL, Roman LD
- KMID: 2431233
- J Gynecol Oncol.
- 2018 Nov;29(6):e88.
- doi: 10.3802/jgo.2018.29.e88
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
